Attached files

file filename
10-Q - FORM 10-Q - INSPIRE PHARMACEUTICALS INCd10q.htm
EX-31.2 - SECTION 302 CFO CERTIFICATION - INSPIRE PHARMACEUTICALS INCdex312.htm
EX-32.2 - SECTION 906 CFO CERTIFICATION - INSPIRE PHARMACEUTICALS INCdex322.htm
EX-10.1 - AMENDED AND RESTATED LICENSE, DEVELOPMENT AND MARKETING AGREEMENT - INSPIRE PHARMACEUTICALS INCdex101.htm
EX-10.2 - STOCK OPTION AGREEMENT BETWEEN INSPIRE PHARMACEUTICALS, INC. - INSPIRE PHARMACEUTICALS INCdex102.htm
EX-10.3 - RESTRICTED STOCK UNIT AGREEMENT BETWEEN INSPIRE PHARMACEUTICALS, INC. - INSPIRE PHARMACEUTICALS INCdex103.htm
EX-31.1 - SECTION 302 CEO CERTIFICATION - INSPIRE PHARMACEUTICALS INCdex311.htm

 

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of Inspire Pharmaceuticals, Inc. (the “Company”) on Form 10-Q for the period ended September 30, 2010, as filed with the Securities and Exchange Commission (the “Report”), I, Adrian Adams, President & Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

 

  1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

  2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: November 5, 2010    

/s/ Adrian Adams

   

Adrian Adams

President & Chief Executive Officer

(principal executive officer)